COMP005
74 evidence topics · 26 sources
Objective
Primary aim: single dose of COMP360 25 mg versus placebo with psychological support
Secondary aims: durability, long-term safety, and retreatment
Location and study date
Study dates in the registry record
| Milestone | Registry entry |
|---|---|
| Study start (actual) | “2023-01-24” |
| Primary completion (actual) | “2025-05-28” |
| Study completion (actual) | “2026-04-15” |
Number of sites: registry and Form 10-K
Study design
Phase 3 randomized, double-blind, placebo-controlled, parallel-group design
| Design element | Registry entry |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |
Parts A, B, and C as described in the 52-week release
Retreatment criteria in Parts B and C
Concomitant antidepressants permitted after Part A
Eligibility criteria
Key inclusion criteria
Key psychiatric exclusion criteria
Exclusions for prior neuromodulation, psychotherapy, and psilocybin exposure
Treatment
Study arms
| Arm | Registry description |
|---|---|
| Experimental | “25 mg COMP360 Psilocybin” |
| Placebo comparator | “Matched placebo” |
| Intervention | “COMP360 Psilocybin administered under supportive conditions” |
Dosing by study part
Psychological support and monitoring model in the trials
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Primary endpoint as defined by the sponsor
Key secondary endpoint: Sheehan Disability Scale at Week 6
Development and validation of the MADRS
“The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The inner-rater reliability of the new depression scale was high. Scores on the scale correlated significantly with scores on a standard rating scale for depression, the Hamilton Rating Scale (HRS), indicating its validity as a general severity estimate. Its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FDA guidance on primary and secondary endpoints in MDD trials
FDA guidance on the timing of the primary endpoint and durability
European Medicines Agency guidance on rating scales
MADRS total score as the primary efficacy measure in FDA-approved labeling for esketamine in TRD
Outcomes named in the ICER draft scope
Minimal clinically important difference on the MADRS
“To identify the minimal clinically important difference (MCID) for the Montgomery-Asberg Depression Rating Scale (MADRS) in randomised studies of depression, and to cross-validate the estimated MCID.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“MCID estimates for MADRS ranged from 1.6 to 1.9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Clinically meaningful change on the MADRS and SDS in TRD
“Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The relationships between the CGI‐S and the MADRS, SDS and PHQ‐9 were established in a moderately severe TRD population and may not be generalizable to severely ill subjects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Clinical meaning of MADRS response and remission thresholds
“Our results confirm the validity of the commonly used measures for response in MDD trials: a CGI-I score of 2 ('much improved') corresponded to a percentage MADRS reduction from baseline of 48-57%, and a CGI-I score of 1 ('very much improved') to a reduction of 80-84%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If a state of almost complete absence of symptoms were required for a definition of remission, a MADRS total score would be <8, because such scores corresponded to a CGI-S score of 2 ('borderline mentally ill').” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No consensus has emerged regarding an appropriate cutoff for defining remission on the Montgomery-Asberg Depression Rating Scale (MADRS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of a narrow definition of remission, which requires a complete absence of clinically significant symptoms of depression, the optimal MADRS cutoff was < or = 4. On the basis of a broader definition, the optimal cutoff was < or = 9.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response and remission definitions used by the company
Statistical analysis description
Number of participants (Planned and analyzed)
Participants dosed in Part A
Participants analyzed at Week 6 in the 25 mg arm
Description of analysis sets
Efficacy analyses by study part
Results
Participant disposition
Randomized and dosed participants
Participants in the 25 mg arm at Week 6
Second administration in Part B
Entry into and dosing in open-label Part C
Baseline characteristics
Demographics
| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
|---|---|---|
| Female, n (%) | “93 (54.4)” | “47 (54.0)” |
| White, n (%) | “149 (87.1)” | “78 (89.7)” |
| Asian, n (%) | “11 (6.4)” | “4 (4.6)” |
| Black or African American, n (%) | “6 (3.5)” | “2 (2.3)” |
| American Indian or Alaska Native, n (%) | “0” | “1 (1.1)” |
| Other race, n (%) | “5 (2.9)” | “2 (2.3)” |
| Age, years, mean (SD) | “45.9 (13.4)” | “45.3 (14.4)” |
| Age, years, minimum and maximum | “19, 77” | “22, 72” |
| Age ≥65 years, n (%) | “15 (8.8)” | “11 (12.6)” |
| Prior psilocybin experience, n (%) | “5 (2.9)” | “5 (5.7)” |
| Prior psychedelic experience including psilocybin, n (%) | “8 (4.7)” | “6 (6.9)” |
| BMI, kg/m2, mean (SD) | “28.4 (6.2)” | “27.7 (6.1)” |
Treatment history and baseline MADRS
| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
|---|---|---|
| Failed treatments in current episode: 1, n (%) | “2 (1.2)” | “1 (1.1)” |
| Failed treatments in current episode: 2, n (%) | “114 (66.7)” | “62 (71.3)” |
| Failed treatments in current episode: 3, n (%) | “45 (26.3)” | “19 (21.8)” |
| Failed treatments in current episode: 4, n (%) | “10 (5.8)” | “4 (4.6)” |
| Failed treatments in current episode: 5, n (%) | “0” | “1 (1.1)” |
| Treatments withdrawn in screening: 0, n (%) | “58 (33.9)” | “26 (29.9)” |
| Treatments withdrawn in screening: 1, n (%) | “38 (22.2)” | “32 (36.8)” |
| Treatments withdrawn in screening: 2, n (%) | “50 (29.2)” | “21 (24.1)” |
| Treatments withdrawn in screening: more than 2, n (%) | “25 (14.6)” | “8 (9.2)” |
| MADRS total score at baseline, mean (SD) | “31.5 (5.5)” | “31.5 (5.9)” |
| Mild (11-19), n (%) | “1 (0.6)” | “2 (2.3)” |
| Moderate (20-30), n (%) | “73 (42.7)” | “33 (37.9)” |
| Severe (≥31), n (%) | “97 (56.7)” | “52 (59.8)” |
Depression diagnosis history
| Characteristic | COMP360 25 mg (N=171) | Placebo (N=87) |
|---|---|---|
| Length of current episode, months, mean (SD) | “34.1 (29.1)” | “38.6 (33.0)” |
| Current episode less than 1 year, n (%) | “30 (17.5)” | “20 (23.0)” |
| Current episode 1-2 years, n (%) | “52 (30.4)” | “19 (21.8)” |
| Current episode more than 2 years, n (%) | “89 (52.0)” | “48 (55.2)” |
| Lifetime depressive episodes, mean (SD) | “7.7 (10.9)” | “7.2 (7.6)” |
| Lifetime episodes 2-5, n (%) | “107 (62.6)” | “54 (62.1)” |
| Lifetime episodes 6-10, n (%) | “40 (23.4)” | “21 (24.1)” |
| Lifetime episodes more than 10, n (%) | “23 (13.5)” | “12 (13.8)” |
Efficacy results
Part A: primary endpoint, change in MADRS total score at Week 6
Part A: least squares mean differences in MADRS by visit
| Visit | COMP360 25 mg vs placebo, LS mean difference (95% CI), p-value |
|---|---|
| Day 2 | “-4.7 (-7.0, -2.3), p<0.001” |
| Week 1 | “-7.2 (-9.6, -4.8), p<0.001” |
| Week 3 | “-5.2 (-7.4, -2.9), p<0.001” |
| Week 6 (primary) | “-3.6 (-5.7, -1.5), p<0.001” |
Part A: post hoc analysis of participants with at least 25% MADRS reduction at Week 6
Part B: blinded follow-up and retreatment through Week 26
Part B: remission after a second dose among Week 6 responders who had not remitted
Part C: open-label 25 mg dose in participants originally randomized to 25 mg
Part C: first 25 mg dose in participants originally randomized to placebo
Part C: response and remission after the open-label 25 mg dose
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Safety summary through Week 26
Treatment-emergent adverse events in Part A, through Week 6
| Event | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TEAE up to Week 6 | “120 (70.2)” | “34 (39.1)” |
| Any serious TEAE up to Week 6 | “4 (2.3)” | “1 (1.1)” |
| Any TEAE with onset on day of dosing | “118 (69.0)” | “23 (26.4)” |
| Resolved within 1 day | “111 (64.9)” | “22 (25.3)” |
| Resolved after more than 1 and up to 2 days | “15 (8.8)” | “2 (2.3)” |
| Resolved after more than 2 days | “22 (12.9)” | “5 (5.7)” |
Treatment-emergent adverse events in Part A with incidence above 5%
| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TEAE | “86 (50.3)” | “12 (13.8)” |
| Headache | “42 (24.6)” | “10 (11.5)” |
| Nausea | “35 (20.5)” | “3 (3.4)” |
| Hallucination, visual | “24 (14.0)” | “0” |
| Anxiety | “14 (8.2)” | “2 (2.3)” |
| Dizziness | “10 (5.8)” | “2 (2.3)” |
| Illusion | “9 (5.3)” | “1 (1.1)” |
Treatment-emergent adverse events through Week 26
| Event | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TEAE up to Week 26 | “145 (84.8)” | “52 (59.8)” |
| Any serious TEAE up to Week 26 | “8 (4.7)” | “2 (2.3)” |
| Any TEAE with onset on day of dosing | “121 (70.8” | “25 (28.7)” |
| Resolved within 1 day | “115 (67.3)” | “24 (27.6)” |
| Resolved after more than 1 and up to 2 days | “16 (9.4)” | “2 (2.3)” |
| Resolved after more than 2 days | “22 (12.9)” | “5 (5.7)” |
| MedDRA preferred term (incidence above 10% in the 25 mg arm) | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TEAE | “145 (84.8)” | “52 (59.8)” |
| Headache | “61 (35.7)” | “16 (18.4)” |
| Nausea | “44 (25.7)” | “5 (5.7)” |
| Hallucination, visual | “27 (15.8)” | “0” |
| Anxiety | “22 (12.9)” | “3 (3.4)” |
Treatment-emergent serious adverse events through Week 26
| MedDRA preferred term | COMP360 25 mg (N=171), n (%) | Placebo (N=87), n (%) |
|---|---|---|
| Any TESAE | “8 (4.7)” | “2 (2.3)” |
| Suicidal ideation | “4 (2.3)” | “0” |
| Depression suicidal | “1 (0.6)” | “0” |
| Major depression | “0” | “1 (1.1)” |
| Cellulitis | “1 (0.6)” | “0” |
| Diverticulitis | “1 (0.6)” | “0” |
| Urinary tract infection bacterial | “0” | “1 (1.1)” |
| Clavicle fracture | “1 (0.6)” | “0” |
| Rib fracture | “1 (0.6)” | “0” |
| Pneumothorax | “1 (0.6)” | “0” |
| Anaphylactic reaction | “1 (0.6)” | “0” |
Suicidality: data safety monitoring board statement, June 2025
Suicidality: serious adverse events across COMP005 and COMP006
Study limitations
Summary: functional unblinding, placebo comparator, observed-case and open-label follow-up, preliminary data
COMP005 compared COMP360 25 mg with a matched placebo, and the company states that concerns about functional unblinding and expectancy bias could hinder the interpretability or regulatory acceptability of its trial data. A systematic review reports that psychedelic trials have generally not reported pre-trial expectancy or blinding success and argues that their effect sizes are likely over-estimated. No statistical analyses were performed after the Week 6 primary analysis: Part B and Part C results are observed data, the responder analysis is post hoc, and protocol-allowed antidepressants were permitted in Parts B and C. Part C was open-label and was entered by approximately 70% of participants. The results are preliminary, had not been reviewed by the FDA at the 2025 topline announcement, and are reported in company documents and congress abstracts.
Company-stated risks of functional unblinding and expectancy bias
Regulatory scrutiny of functional unblinding in the phase 3 program
Preliminary topline data not yet reviewed by FDA or published
Descriptive, observed-case, and post hoc analyses after Week 6
Open-label design of Part C
European Medicines Agency guidance on comparators, expectancy, and unblinding in psychedelic trials
Blinding and expectancy confounds in psychedelic trials
“We conduct systematic reviews of psychedelic RCTs using Medline, PsychInfo and EMBASE (Jan 1990 - Nov 2020) and show that currently reported psychedelic RCTs have generally not reported pre-trial expectancy, nor the success of blinding procedures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of studies with a drug control condition (80), 49 (61.2%) used an inert placebo control, 16 (20.0%) used active comparators, 12 (15.0%) used both, and 3 (3.8%) used only different active psychedelic doses as a control.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The majority (81/86; 94%) of studies were blinded, though only 14 (17.3%) included blind assessment; only 8 of these 14 studies assessed participants' blinding. Blinding success, assessed in highly varied ways, was generally poor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Blinding integrity may be compromised by perceived treatment efficacy and adverse effects, introducing bias into outcome assessments.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We recommend collecting data on treatment expectations alongside monitoring blinding integrity to more accurately interpret study results.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Low control-group response in psilocybin depression trials
“In this meta-analysis of 17 acute-phase randomized clinical trials of psilocybin (n = 373), esketamine (n = 573), or SSRIs (n = 4014), patients receiving control treatments in psilocybin trials had significantly worse depression outcomes compared with those receiving control treatments in trials of esketamine or SSRIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocybin in trials for depression has been given in psychedelic doses, which risks making functional unblinding both immediate and prevalent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, since administration is usually supervised, unblinding may also extend to study personnel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Comparison with open-label antidepressants under equal unblinding conditions
“Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding, which biases results when comparing PAT with blinded interventions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Contrary to the first of 3 hypotheses, PAT (8 trials; 249 patients) was no more effective than open-label TAD treatment (16 open-label TAD trials; 7921 patients), with an estimated difference of 0.3 favoring open-label TADs (95% CI, -1.39 to 1.98; P = .73).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline and systematic review assessments of psilocybin trial methods
“Small sample sizes and functional unblinding were major limitations in all studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Future trials should publish trial protocol and SAPs, use clinician-rated outcomes accessed by a blinded rater, evaluate blinding of intervention, and consider measuring expectancy and therapeutic fidelity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote